Insmed Incorporated (0JAV.L)

20.80 +3.89 (+23.00%) At close: 03:39PM BST

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com

Sector(s): 
Industry: 
Full-time employees: 613

Key executives

Name	Title	Pay	Exercised	Year born
Mr. William H. Lewis J.D., M.B.A.	Pres, CEO & Chairman	1.32M	5.32M	1969
Ms. Sara M. Bonstein MBA	Chief Financial Officer	702.22k	N/A	1981
Mr. Roger Adsett	Chief Operating Officer	871.13k	N/A	1969
Ms. S. Nicole Schaeffer	Chief People Strategy Officer	660.81k	1.18M	1968
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer	787.6k	N/A	1964
Mr. John Goll III	Sr. VP & Chief Accounting Officer	N/A	N/A	N/A
Eleanor Barisser	Associate Director of Investor Relations	N/A	N/A	N/A
Mr. Michael Alexander Smith	Sr. VP & Gen. Counsel	N/A	N/A	1978
Mandy Fahey	Sr. Director of Corp. Communications	N/A	N/A	N/A
Mr. Drayton Wise	Sr. VP & Head of United States	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate governance

Insmed Incorporated’s ISS governance QualityScore as of 1 May 2022 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.